NeuBase Therapeutics (NBSE) 10-Q2016 Q1 Quarterly report

Filed: 9 Feb 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Good

New words: AAO, Abicipar, accessed, aggregate, alter, bankruptcy, biodegradable, biomedical, burn, cautioned, closure, comprehensive, comprised, compromise, concept, critical, cutoff, damage, damaging, decade, deter, employee, enabling, encompassed, Enivsia, error, expansion, Eylea®and, flat, governmental, GreyBug, health, hereof, hydrophilic, hydrophobic, IA, implied, infrastructure, injunction, Kala, Landscape, leaving, loan, malfeasance, matrix, Medicaid, Medicare, MPP, multicenter, naive, nanoparticle, nonrenewal, Obama, offset, oversight, pace, particle, partnership, passed, passive, past, Pegol, permanent, pharmacodynamic, pharmacokinetic, pharmacology, plant, polymer, post, predictor, prepaid, presence, prespecified, PRINT, privacy, proof, publicly, randomly, readily, Ready, recognition, reincorporated, reincorporation, risen, sector, semiannual, SPA, stolen, store, stored, substance, summary, superior, supplant, supplier, temporary, Therapeutix, threshold, toxicology, turn, Tyrogenex, unclear, unobservable, unsolicited, versatility, violation, vivo, vulnerable, warranty

Removed: Alcon, audited, Avalanche, biological, breast, cancer, caption, cautionary, characterized, circumvent, conference, consist, constitute, consummated, discontinued, dose, effected, entirety, environment, escalation, estimate, examine, extended, finance, forum, forward, FovistaTM, fractional, gene, import, improving, income, initiating, instance, iSonep, June, licensure, LPath, Macula, Note, noted, obesity, occurred, October, offering, pegylated, Pfizer, phosphatase, pursuing, ranibizumab, retroactively, reverse, rounding, slightly, split, twenty, underwritten, Xcovery

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NBSE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

OHR Pharmaceutical, Inc 10-Q

Exhibit 32.2

Certification of Principal Financial Officer

Pursuant to 18 U.S.C Section 1350,

As Adopted Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

Not Filed Pursuant to the Securities Exchange Act of 1934

In connection with the Quarterly Report of Ohr Pharmaceutical, Inc. (the“Company”) on Form 10-Q for the period ending December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the“Report”), I, Sam Backenroth, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 9, 2016

/s/ Sam Backenroth
Name: Sam Backenroth
Title: Chief Financial Officer (Principal Financial Officer)